MétaCan
Menu
Back to cohort
Record W4397007854 · doi:10.1016/j.esmoop.2024.103035

27P Impact of chemotherapy (CT) use and stromal tumor-infiltrating lymphocytes (sTILs) in stage I triple-negative breast cancer (TNBC)

2024· article· en· W4397007854 on OpenAlexaff
Vittoria Barberi, François Panet, L. Joval, Juliana Jaramillo, I. Pimentel, M. Borrell Puy, Meritxell Bellet Ezquerra, M.A. Arumi de Dios, L. Sanz Gómez, E. Monescillo Calzado, C. Ortiz, M.A. Rezqallah Aron, Santiago Escrivá-de-Romaní, M. Cruellas Lapena, J.A. Jimenez, Martín Espinosa-Bravo, V. Peg Cámara, C. Saura Manich, Maila Dayane Capuchinho de Oliveira

Bibliographic record

VenueESMO Open · 2024
Typearticle
Languageen
FieldMedicine
TopicCancer Immunotherapy and Biomarkers
Canadian institutionsMcGill University
Fundersnot available
KeywordsTriple-negative breast cancerStage (stratigraphy)Triple negativeStromal cellChemotherapyBreast cancerMedicineOncologyCancerPathologyInternal medicineBiology

Abstract

fetched live from OpenAlex

The optimal systemic treatment for stage I TNBC remains unclear, given the lack of well-designed randomized trials. sTILs have emerged as a prognostic biomarker in early TNBC. We aimed to study the impact of (neo)adjuvant CT use and sTILs in the prognosis of pts with stage I TNBC. Pts with stage I TNBC (ER<10% and HER2-0/low) treated at Vall d’Hebron Hospital between 2006 and 2021 were reviewed. sTILs were evaluated at the surgery specimen and/or at the diagnostic biopsy, as per the international immuno-oncology working group guidelines. The effect of (neo)adjuvant CT and sTILs on invasive disease-free survival (iDFS), distant disease-free survival (DDFS), and overall survival (OS) was evaluated. Statistical significance (p<0.05) was determined using the log-rank test. 108 patients were identified (median age 56, 35% pre-menopausal). The majority of patients had tumors ≥10mm (75%), grade 3 (61%), and received CT (79%). Patients not receiving CT had a median age of 75, 17% were pT1a tumors and 30% had favorable histotypes. sTILs could be assessed in 79/108 (73%); 34% had sTILs >50%, which associated with higher grade and Ki67. With a median follow-up of 7.2 years (IC: 3.0 – 21.8), 19/108 (18%) had a progression event, 9 (8%) distant metastases. 5y iDFS, DDFS, and OS rates are presented in the table. (Neo)adjuvant CT was not associated with better iDFS (p=.53), DDFS (p=.66) or OS (p=.89). In multivariate analyses for the survival endpoints, no interaction was observed between sTILs (both as categorical and continuous variables) and CT use.Table: 27P5-year ratesNiDFS (%)DDFS (%)OS (%)Overall population10883.691.298.9sTILs >50%2788.7100100sTILs <50%5285.6∗p=.63.93.8†p=.34.97.6‡p=.68.CT, overall8583.191.3100CT and sTILs>50%2387100100CT and sTILs<50%368997100No CT, overall2386.190.995.2No CT and sTILs>50%4100100100No CT and sTILs<50%16808793∗ p=.63.† p=.34.‡ p=.68. Open table in a new tab In this retrospective cohort, a high proportion of patients with stage I TNBC received CT, which was not associated with better outcomes, irrespectively of the abundance of sTILs. The role of (neo)adjuvant CT in stage I TNBC should be studied in prospective trials to identify patients that can be spared systemic treatment.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.006

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.029
GPT teacher head0.350
Teacher spread0.321 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueESMO OpenSame topicCancer Immunotherapy and BiomarkersFrench-language works237,207